Ratings Cellectis S.A.

Equities

ALCLS

FR0010425595

Market Closed - Euronext Paris Other stock markets 11:35:27 2024-04-23 am EDT			5-day change	1st Jan Change
2.42 ^EUR	-1.43%		+2.54%	-12.45%

Apr. 22	Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	CI
Apr. 22	European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CELLECTIS S.A.	-12.45%	186M	C
IQVIA HOLDINGS INC.	+3.13%	43.43B	B
LONZA GROUP AG	+48.83%	41.69B	A
MODERNA, INC.	+8.49%	41.31B	B-
CELLTRION, INC.	-10.82%	27.14B	C
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B	B-
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.47B	B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	12.33B	C+
MEDPACE HOLDINGS, INC.	+32.83%	12.59B	C+
UNITED THERAPEUTICS CORPORATION	+6.63%	11.03B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes